Longvida®: New Study

Written by

“Evaluation of the efficacy and safety of Capsule Longvida® Optimized Curcumin (solid lipid curcumin particles) in knee osteoarthritis: a pilot clinical study” is the title of the latest publication about Longvida® in the Journal of Inflammation Research.

The independent double-blind, placebo-controlled, human clinical trial demonstrated that oral administration of Longvida® (400mg twice a day) was found to be effective and safe in alleviating symptoms in patients suffering from knee osteoarthritis when administered for 90 days. This improvement was comparable to sub-therapeutic doses of ibuprofen. Significant improvements in VAS and WOMAC scores compared to baseline were observed. Longvida® was found to be “faster acting” in providing “pain relief” compared to ibuprofen in the first 30 days. No serious adverse events were reported, therefore this study further confirms the safety of Longvida®.

 For more information, download the full version of the study here. Please make sure you are logged as a registered user before accessing the product page.
Back to the News Section